Palivizumab

Palivizumab is a monoclonal antibody used for the prevention of respiratory syncytial virus infection in infants at high risk of infection.

Brands
Adult Dose
Dose: 15 mg/kg of body weight
Single Dose: 15 (15)
Frequency: As recommended.
Route: IM
Instructions:
Neonatal
Paedriatic
Characteristics
.
Contraindications
Palivizumab
Effects
The symptomatic adverse reactions produced by Palivizumab are more or less tolerable and if they become severe, they can be treated symptomatically, these include Vomiting, Diarrhea, Fever, Nervousness, Rashes, Pain, Cough, Abnormal LFT, Rhinitis, Wheezing, Injection-site reactions, Leucopenia.
Indications
Palivizumab is primarily indicated in conditions like Duodenal errosions.
Interactions
No data regarding the interactions of Palivizumab was found.
Interfrence
Risks
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Palivizumab should be used with caution in moderate to severe acute infection or febrile illness; congenital heart disease; thrombocytopenia. Facilities for cardiopulmonary resuscitation must be at hand.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.